Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01211145 · ClinicalTrials.gov registry record · Phase 4
Zomig - Treatment of Acute Migraine Headache in Adolescents
A Phase 4 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,653
- Enrollment target
NCT01211145: Completed Phase 4 study, sponsored by AstraZeneca.
NCT01211145 is a Phase 4 study that has completed, run by AstraZeneca. The registered enrollment target is 1,653 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (219% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01211145, a Phase 4 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,653 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better. This will be done by comparing 3 different doses of Zomig Nasal Spray with placebo nasal spray (inactive treatment).
Interventions
- DRUG Placebo
- DRUG Zolmitriptan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,653 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-10 |
| Phase | Phase 4 |
What the finished NCT01211145 record still lists
NCT01211145 is an interventional study that assigns participants to a tested intervention. Its 1,653 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (219% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01211145 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01211145 about?
NCT01211145 is a clinical study titled "Zomig - Treatment of Acute Migraine Headache in Adolescents". The purpose of this study is to investigate if Zomig® Nasal Spray will help children (age 12-17 years) with migraine headaches feel better. This will be done by comparing 3 different doses of Zomig Nasal Spray with placebo nasal spray (inactive treatment).
What is the current status of trial NCT01211145?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,653 participants. The study started on 2010-09. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01211145?
The interventions under investigation include: Placebo (DRUG), Zolmitriptan (DRUG).
Who is sponsoring clinical trial NCT01211145?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01211145's enrollment target sits among peer trials
1,653 47th of 2000 higher than 1,954 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06401330 · 1,656 participants · Phase 3
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
- NCT04510129 · 1,650 participants
A Multicenter Cancer Biospecimen Collection Study
- NCT05612750 · 1,650 participants · NA
Comparative Effectiveness of Online 8-session CBT vs. 1-Session Empowered Relief for Chronic Pain - The PROGRESS Study
- NCT06215716 · 1,650 participants · Phase 3
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia